Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
June 01, 2017
Ocular Therapeutix™ Presented Phase 3 Data for DEXTENZA™ at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 11, 2017
Ocular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting
May 09, 2017
Ocular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
May 08, 2017
Ocular Therapeutix™ Reports First Quarter 2017 Financial Results
May 05, 2017
Ocular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 02, 2017
Ocular Therapeutix™ to Report First Quarter 2017 Financial Results
May 01, 2017
Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
April 24, 2017
Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer
April 06, 2017
New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract Surgery
March 15, 2017
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results
March 10, 2017
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results
March 08, 2017
Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
February 22, 2017
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
February 09, 2017
Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock
January 24, 2017
Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
January 23, 2017
Ocular Therapeutix, Inc. Announces Public Offering of Common Stock
January 23, 2017
Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™